You are here
From patented antibodies to tumour associated cell surface markers. We have a diverse portfolio with the opportunity to licence agents in pre-clinical to Phase II clinical development.
We are seeking a partner experienced in the field of cell therapy development and in the Chinese regulatory environment to take this technology through to first in man trials in China.Read more
Tumor endothelial markers (TEMs) that are highly expressed in human tumor vasculature compared with vasculature in normal tissue hold clear therapeutic potential.Read more